Rare Form: GSK, NEA Back Orphan Disease Venture Fund

A new fund offering access to European translational research focused on rare diseases has high-profile backers and reunites key players in the successful Prosensa IPO.

A trio involved in one of the best performing 2013 IPOs is hoping to repeat that success with a new fund. Orphan disease play Prosensa Holding BV saw its share price more than double in the first few weeks following its late June debut. [See Deal] (SeeAlso see "Prosensa Debuts On The Nasdaq Hours After Getting Breakthrough Designation For Lead Compound" - Pink Sheet, 28 June, 2013..) Now, two Prosensa investors, Kurma Life Sciences Partners and New Enterprise Associates, and Prosensa's development partner, GlaxoSmithKline PLC, [See Deal] are behind a new venture fund specifically aimed at rare disease companies.

The fund is called Kurma Biofund II. KLS Partners is raising it; NEA and GSK are LPs that will be actively involved with the portfolio companies but will have no...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By 

US green light will further expand sales of the prostate cancer blockbuster.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By 

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By 

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

More from Business

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By 

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By 

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.